PTC THERAPEUTICS, INC. PTCT
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
We have a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The disclosure below summarizes the status of our significant commercial products and clinical-stage programs as of the date of this report, including those with our strategic partners:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $806.8M | $937.8M | $698.8M | $538.6M | $380.8M | $307.0M | $264.7M | $194.4M | $82.7M |
| Cost of revenue | — | — | — | — | — | — | $12.1M | $12.7M | $4.6M | $0 |
| Gross profit | — | — | — | — | — | — | $294.8M | $252.1M | $189.8M | $82.7M |
| R&D | $455.2M | $534.5M | $666.6M | $651.5M | $540.7M | $477.6M | $257.5M | $172.0M | $117.5M | $117.6M |
| SG&A | $347.1M | $300.9M | $332.5M | $326.0M | $285.8M | $245.2M | $202.5M | $153.5M | $121.3M | $97.1M |
| Total operating expenses | $863.7M | $1.11B | $1.38B | $1.15B | $913.0M | $812.5M | $548.1M | $380.4M | $258.7M | $214.8M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M | -$374.4M | -$431.8M | -$241.2M | -$115.7M | -$64.3M | -$132.1M |
| Pre-tax income | $696.6M | -$363.1M | -$696.1M | -$587.5M | -$518.3M | -$402.9M | -$239.9M | -$128.1M | -$77.7M | -$141.5M |
| Income tax | $14.0M | $176.0K | $69.5M | $28.5M | $5.6M | $35.2M | $11.7M | $29.0K | $1.3M | $569.0K |
| Net income | $683.0M | -$363.3M | -$626.6M | -$559.0M | -$523.9M | -$438.2M | -$251.6M | -$128.1M | -$79.0M | -$142.1M |
| EPS, basic | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | — |
| EPS, diluted | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 |
| Shares, diluted (wtd. avg.) | 88.3M | 76.8M | 74.8M | 71.7M | 70.5M | 66.0M | 58.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $984.6M | $779.7M | $610.3M | $295.9M | $197.2M | $216.3M | $295.5M | $169.5M | $111.8M | $58.3M |
| Short-term investments | $960.7M | $360.0M | $282.7M | $130.9M | $583.7M | $894.8M | $398.5M | $58.1M | $79.5M | $173.3M |
| Receivables | $181.6M | $158.6M | $160.8M | $155.6M | $110.5M | $69.9M | $55.5M | $67.9M | $40.4M | $24.9M |
| Inventory | $79.6M | $23.2M | $30.6M | $21.8M | $15.9M | $18.7M | $19.3M | $16.1M | $10.8M | $0 |
| Total current assets | $2.27B | $1.37B | $1.22B | $693.8M | $954.4M | $1.23B | $779.3M | $320.9M | $249.1M | $261.3M |
| Property, plant and equipment | $55.4M | $61.0M | $87.1M | $72.6M | $52.6M | $33.8M | $21.5M | $12.7M | $8.4M | $7.4M |
| Goodwill | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $0 | — |
| Other intangibles | $388.8M | $118.8M | $379.5M | $705.9M | $724.8M | $715.3M | $710.5M | $701.0M | $133.0M | $0 |
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $391.7M | $269.3M |
| Accounts payable | $45.5M | $17.3M | $6.0M | $27.3M | $23.0M | $18.7M | $10.3M | $6.0M | $15.3M | $6.3M |
| Short-term debt | $286.6M | — | — | — | $149.5M | — | $20.0M | $11.7M | $0 | — |
| Total current liabilities | $968.4M | $581.0M | $603.1M | $406.2M | $509.3M | $277.3M | $235.9M | $166.8M | $82.0M | $49.6M |
| Long-term debt | — | $285.4M | $284.2M | $571.7M | $281.9M | $309.1M | $293.9M | $141.3M | $145.0M | $98.2M |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768.5M | $235.2M | $149.8M |
| Retained earnings | -$2.96B | -$3.65B | -$3.28B | -$2.66B | -$2.10B | -$1.63B | -$1.19B | -$938.9M | -$814.1M | -$735.1M |
| Total equity | -$205.3M | -$1.10B | -$818.6M | -$347.1M | $1.4M | $482.0M | $594.3M | $350.7M | $156.4M | $119.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M | -$194.1M | -$98.6M | -$27.6M | -$10.1M | -$103.6M |
| Depreciation and amortisation | $38.8M | $75.7M | $236.6M | $128.8M | $64.1M | $43.5M | $32.2M | $26.1M | $17.7M | $3.3M |
| Stock-based compensation | $74.5M | $74.6M | $101.6M | $110.3M | $103.5M | $70.3M | $42.1M | $33.3M | $30.6M | $35.0M |
| Capital expenditure | $8.9M | $6.5M | $28.4M | $32.0M | $28.2M | $17.8M | $13.8M | $7.1M | $3.1M | $1.8M |
| Investing cash flow | -$862.0M | $44.2M | -$176.7M | $290.2M | $219.2M | -$561.5M | -$387.2M | -$42.6M | $13.1M | $104.5M |
| Financing cash flow | $331.1M | $255.9M | $646.4M | $168.0M | $20.9M | $668.7M | $613.2M | $131.6M | $44.2M | $968.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-045528.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.7M | $194.4M | $264.7M | $307.0M | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B |
| Gross profit | $82.7M | $189.8M | $252.1M | $294.8M | — | — | — | — | — | — |
| Net income | -$142.1M | -$79.0M | -$128.1M | -$251.6M | -$438.2M | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $683.0M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Other event Item 8.01
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |